13单体与13q缺失在接受自体移植的多发性骨髓瘤患者中的预后影响
该单中心回顾性研究纳入2010至2021年间接受自体造血干细胞移植且有FISH结果的多发性骨髓瘤患者1680例,其中591例(35.2%)存在del(13q)/-13。孤立性del(13q)/-13与更短的无进展生存和总生存相关,合并高危细胞遗传学异常时预后最差,多因素Cox回归证实其为独立不良预后因素。
要点
- del(13q)/-13见于35.2%的移植患者,孤立存在即与更短PFS和OS相关
- 合并高危细胞遗传学异常者预后最差,中位PFS 33.9个月、OS 81.6个月
- 多因素分析显示孤立性del(13q)/-13是PFS和OS的独立不良因素
核心结论
- del(13q)/-13在接受autoHSCT的多发性骨髓瘤患者中与更差的无进展生存和总生存独立相关。
- del(13q)/-13与高危细胞遗传学异常共存时呈现叠加的不良预后效应。
研究设计与样本
- 单中心回顾性研究,纳入2010至2021年接受autoHSCT且有FISH结果的多发性骨髓瘤患者1680例。
- 按是否合并高危细胞遗传学异常及del(13q)/-13进行分组比较,并采用多因素Cox回归分析。
主要发现
- 591例(35.2%)检出del(13q)/-13。
- 与无高危细胞遗传学异常且无del(13q)/-13者相比,孤立性del(13q)/-13者中位PFS为37.3 vs. 64.6个月,中位OS为105.4 vs. 131.0个月。
- 合并高危细胞遗传学异常与del(13q)/-13者预后最差,中位PFS 33.9个月、中位OS 81.6个月。
- 多因素Cox回归显示孤立性/非高危相关del(13q)/-13与更差PFS独立相关(HR 1.36,95%CI 1.17-1.58,p=0.0001),与更差OS独立相关(HR 1.49,95%CI 1.21-1.84,p=0.0002)。
关键数值与推荐
- del(13q)/-13检出率35.2%(591/1680)。
- 孤立性del(13q)/-13:中位PFS 37.3个月 vs. 64.6个月,中位OS 105.4个月 vs. 131.0个月。
- 合并高危细胞遗传学异常与del(13q)/-13:中位PFS 33.9个月,中位OS 81.6个月。
- PFS的HR 1.36(95%CI 1.17-1.58,p=0.0001);OS的HR 1.49(95%CI 1.21-1.84,p=0.0002)。
临床怎么用
- 对准备行autoHSCT的多发性骨髓瘤患者,FISH检出del(13q)/-13可提示PFS和OS预后更差。
- del(13q)/-13合并高危细胞遗传学异常者预后最差,可考虑更密切的随访与风险分层管理。
局限性
- 回顾性、单中心设计,结果的外推需谨慎。
- 仅纳入有FISH结果且接受autoHSCT的患者,存在选择偏倚可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Deletion (13q)/monosomy 13 (del[13q]/-13) is common in multiple myeloma (MM), but its independent prognostic value remains unclear, particularly in patients treated with modern therapy and upfront autologous haematopoietic stem cell transplantation (autoHSCT). This study aimed to assess its impact on progression-free survival (PFS) and overall survival (OS), and to evaluate its prognostic impact in the context of established high-risk cytogenetic abnormalities (HRCA). We conducted a retrospective, single-centre study of MM patients undergoing autoHSCT between 2010 and 2021 with available fluorescence in situ hybridization results. Among 1680 patients, del(13q)/-13 was identified in 591 (35.2%). Compared with patients without HRCA or del(13q)/-13, isolated del(13q)/-13 was associated with shorter median PFS (37.3 vs. 64.6 months) and OS (105.4 vs. 131.0 months). Patients with concurrent HRCA and del(13q)/-13 had the poorest outcomes, with median PFS and OS of 33.9 and 81.6 months, respectively. Multivariable Cox regression confirmed that isolated/non-HRCA-associated del(13q)/-13, was independently associated with inferior PFS (hazard ratio [HR] 1.36, 95% confidence interval [CI]: 1.17-1.58, p = 0.0001) and OS (HR 1.49, 95% CI: 1.21-1.84, p = 0.0002). Del(13q)/-13 is independently associated with inferior PFS and OS in MM patients undergoing autoHSCT, with an additive adverse effect when co-occurring with HRCA.
引用
- Mikulski DM, Marcoux C, Tanner MR, et al. Prognostic impact of monosomy 13 and deletion of 13q in multiple myeloma patients undergoing upfront autologous transplantation. Br J Haematol. 2026. PMID: 42494235. doi:10.1111/bjh.70694
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。